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 ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
Valdecoxib is an effective treatment option to improve pain in adults with osteoarthritis of the 
hip or knee.  
 
STUDY DESIGN:  This review consists of three randomized control trials; two were published 
in 2002 and the third in 2006.  
 
DATA SOURCES:  Sources were studies comparing groups taking Valdecoxib 10mg QD to 
placebo, which were found via Pubmed, MEDLINE, Ovid, and Cochrane databases.  
 
OUTCOMES MEASURED:  The three articles measured various outcomes: pain improvement, 
stiffness, physical improvement, adverse effects, and onset of analgesia during acute pain flare.  
Outcomes were measured via the Patient’s Assessment of Arthritis Pain- Visual Analog Scale 
(PAAP-VAS), WOMAC osteoarthritis, Patient’s (PaGAA) and Physician’s (PhGAA) Global 
Assessment of Arthritis.   
 
RESULTS:  Kivitz et al found that Valdecoxib 10mg & 20mg daily doses were similar in 
efficacy and both were superior to placebo.  Valdecoxib 5mg was not found to be superior to 
placebo.5 Makarowski et al also found that Valdecoxib 5mg and 10mg QD were superior to 
placebo.  They also found that Valdecoxib 10mg QD was superior in efficacy to Valdecoxib 5mg 
QD.6 Moskowitz et al found that patients had both a significant improvement in pain at 3 hours 
with Valdecoxib as compared to placebo, and a statistically significant increase in percentage of 
patients with analgesia after 4hrs compared to placebo.7  
 
CONCLUSION:  These three randomized control trials all concluded that Valdecoxib is superior 
to placebo in doses of at least 10mg as compared to placebo. Further studies should review safety 
of Valdecoxib in a risk/benefit analysis to provide useful conclusions about the continued use of 
it for treatment of osteoarthritis.  
 
KEY WORDS:  “Osteoarthritis”, “Valdecoxib” 
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INTRODUCTION 
 Osteoarthritis is a very common condition in the adult and older populations in the US.   
Although there are with various forms of treatment focused on symptom improvement, there is 
currently no cure for OA.1 Also known as degenerative joint disease, OA is the most common 
form of arthritis, classified as Idiopathic or Secondary.  Osteoarthritis is usually diagnosed by 
symptomatology and radiographic findings, most commonly affecting the hips, knees, hands, and 
feet.  
 In the United States, osteoarthritis affects 13.9% of adults 25 years and older and 33.6% 
of those over 65 years.1 In 2005 it was estimated that 26.9 million US adults were affected by 
OA. Additionally, in 1997 it was estimated that approximately 409,000 hospitalizations occur 
annually with osteoarthritis as the principal diagnosis. Osteoarthritis is the most common cause 
of disability in elderly patients in the developed world.2 OA is not only affecting thousands of 
patients annually, it is also very costly. Job-related osteoarthritis costs approximately $3.4-13.2 
billion per year, and it was estimated that $7.9 billion was spent on hip and knee replacements in 
1997.1  
 Specific causes of OA are unknown, but it is believed to be a result of both mechanical 
and molecular events in the affected joint.1 OA is characterized by focal and progressive loss of 
hyaline cartilage as well as bony changes like osteophytes, bony sclerosis and joint space 
narrowing.1  Patients often experience joint pain, stiffness, and loss of ADLs due to 
osteoarthritis.  
 Initial treatment regimens include moderate physical activity, weight loss, and use of 
assistive devices.3  Pharmacologic treatments typically start with oral acetaminophen for mild 
disease, and then progress to oral NSAIDs of various strengths including selective COX-2 
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inhibitors.3  Diclofenac—a topical NSAID—has also shown some efficacy in knee and hand 
OA.3  Other treatment options include intra-articular injections of corticosteroids or sodium 
hyaluronate.3  The only curative option for hip and knee arthritis at this point is surgical 
replacement of the joint, which has many limitations including cost, lifespan of the replacement 
joint, and patient’s ability to undergo major surgery.3 
Chronic NSAID use has various side effects including GI upset and ulceration, so it has 
been proposed that COX-2 specific inhibitors such as Valdecoxib may be equally as effective 
without the adverse affects of non-selective NSAIDs.4 Various studies are looking at the safety 
and efficacy of COX-2 specific inhibitors for osteoarthritis patients since their introduction.4  
Although Valdecoxib has recently been pulled off the market, it is important still to look at the 
effects of all different COX-2 inhibitors to make improvements for the future.   
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not 
Valdecoxib is an effective treatment option to improve pain in adults with osteoarthritis of 
the hip or knee. 
METHODS 
 The three articles used in this selective EBM review were found via Ovid, Medline, 
Pubmed, and Cochrane databases.  All articles selected were published in English in peer-
reviewed journals between 2002 and 2006, using the keywords “Valdecoxib” and 
“osteoarthritis” to search the above mentioned databases.  Inclusion criteria for the studies 
selected require the use of patient oriented outcomes (POEMs), RCT’s, studies published 
after 1996, and those evaluating efficacy of Valdecoxib.  Exclusion criteria involved the use 
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of DOE outcome measures, studies that looked at pediatric populations, and those that only 
looked at safety profiles of Valdecoxib. 
 All three studies were double blinded, randomized controlled trials looking at adult 
populations over the age of 18 with diagnosed osteoarthritis of the hip or knee. The outcomes 
measured in these studies were efficacy of Valdecoxib for the treatment of osteoarthritis of 
the hip or knee.  Each study utilized an intervention of Valdecoxib po daily, although other 
interventional drugs were used in comparison as well.  The comparison group in every study 
reviewed was one that received placebo. Two of the studies evaluated alleviation of pain with 
consistent daily use of Valdecoxib, and the third study evaluated onset of analgesia during 
acute pain flare with the addition of Valdecoxib.  A summary of statistics includes numbers 
needed to treat (NNT), mean change from baseline, confidence interval (CI), and p-values.  
The demographics of included studies can be found in Table 1.  
Table 1: Demographics & Characteristics of included studies 
Study Type # 
pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W
/
D 
Intervention 
Kivitz5 RCT  1, 
016 
59.8 
± 
10.9 
years 
Ambulatory 
adults with mod-
severe OA of the 
knee 
Pts with baseline 
scores >40mm on 
PAAP-VAS & 
“poor” or “very 
poor” on PaGAA 
and PhGAA 
Pts with inflammatory arthritis, 
gout, pseudogout, paget’s, or any 
other chronic pain syndrome; 
Pts with OA of hip ipsilateral to 
Index Knee (IK), severe anserine 
bursitis, acute joint trauma, 
complete loss of articular cartilage 
on IK 
2
6
9 
Randomized to 
control 
(placebo) or 
experimental 
groups 
receiving 
Valdecoxib 
5mg, 10mg, 
20mg QD, or 
Naproxen 
500mg BID 
Maka-
rowski6 
RCT 467 62.4 
± 
11.8 
years 
Pts with 
symptomatic OA 
of the hip: pain + 
2 of the 
following: 
ESR<20mm/ hr, 
radiographic 
osteophytes, joint 
space narrowing; 
Baseline PAAS-
VAS ≥ 40 
PaGAA or 
Pts with inflammatory arthritis, 
gout, pseudogout, paget’s, or any 
chronic pain syndrome; 
Pts with OA of the knee ipsilateral 
to the Index Hip (IH), symptomatic 
trochanteric bursitis, or acute joint 
trauma of IH; 
Pts with complete loss of articular 
cartilage on WT-bearing xray of IH 
Pts with active GI disease, GI tract 
ulceration within 30 days of study 
medication, or significant bleeding 
2
0
9 
Randomized 
to control 
group 
(placebo) or 
experimental 
groups 
receiving 
Valdecoxib 
5mg or 10mg 
QD, or 
Naproxen 
500mg BID 
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PhGAA “poor” or 
“very poor” 
disorder 
Mosko
-witz7 
RCT 530 63.9 
± 9.2 
years 
≥45 years old with 
knee OA; 
Functional 
capacity 
classification I or 
II; OA in flare 
state at baseline 
assessment: 
defined as ≥3 of 
the following: 
PAAP-VAS 
≥40mm, Lequesne 
OA severity index 
≥7, PaGAA or 
PhGAA of “poor” 
or “very poor” 
Inflammatory arthritis or acute joint 
trauma of Index Joint (IJ); Hx of 
malignancy, active GI disease, 
chronic or acute renal/hepatic/ 
coagulation disorder; Abnl 
screening lab values >1.5x the 
upper limit for AST or ALT, serum 
creatinine ≥2.0, or other lab 
abnormality within 14 days of 
baseline assessment; Pts who 
received oral, IM, or intra-articular 
corticosteroids within 8 weeks, or 
intra-articular hyaluronic acid in IJ 
with in 6 months of study drug 
admin; Pts who have taken 
anticoagulants, NSAIDs, COX-2 
specific inhibitors or analgesic 
agents 
9
5 
Randomized 
to control 
group 
(placebo) or 
experimental 
groups 
receiving 
Valdecoxib 
10mg QD or 
Rofecoxib 
25mg QD 
 
OUTCOMES MEASURED 
The outcomes measured in the reviewed studies are all Patient Oriented Evidence that 
Matters (POEMs); in this case pain improvement and onset of analgesia.  Kivitz et al5 
measured pain improvement using the Patient’s (PaGAA) and Physician’s (PhGAA) Global 
Assessment of Arthritis, Patient’s Assessment of Arthritis Pain- Visual Analog Scale (PAAP-
VAS), and Western Ontario & McMaster Universities (WOMAC) OA indexes reported by 
patients and physicians.  In this study, baseline measurements were made for comparison and 
then subsequent assessments were done with each tool at 2, 6, and 12 weeks.  Analysis was 
done by least square mean (LSM) change from baseline and reported as statistically 
significant based on p-values and confidence intervals.  Makarowski et al6 had a similar 
study design for reporting efficacy; they measured mean changes from baseline using 
PaGAA, PhGAA, PAAP-VAS and WOMAC scales to report pain improvement.  Again, 
LSM changes from baseline were reported at 2, 6, and 12 weeks and analyzed via p-values 
and confidence intervals compared to placebo. Moskowitz et al7 measured onset of analgesia 
during an acute pain flare, defined as ≥3 of the following: PAAP-VAS ≥40mm, Lequesne 
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OA severity index ≥7, PaGAA or PhGAA of “poor” or “very poor.”  Patients who met 
criteria for the study were asked to walk for 10 minutes prior to baseline measurements using 
the WOMAC scale.  Pain intensity (PI) on a visual analog scale (VAS) was then measured at 
0.5, 1.0, 1.5, 2, 3, 4, 5, and 6 hours after administration of study medication, each following a 
10-minute walk.  Statistical analysis of the data was based on percentage of patients with 
“analgesia” at each time interval, defining onset of analgesia as a 25% reduction in PI from 
baseline.  
RESULTS  
 In the study done by Kivitz et al,5 1019 patients were recruited from 85 different 
primary care and rheumatology specialty settings across the United States and Canada.  
Patients were randomized into treatment groups and self-administered oral medications.5 
Patients and researchers were blinded during this process.5  For all three studies, statistical 
analysis was done on the intent to treat (ITT) population, which included those who 
randomized and had taken at least one dose of study medication.  This particular study only 
included continuous data that could not be converted into dichotomous data.  
 Three patients did not take any study medication and therefore were not included in 
efficacy analysis.  Of the 1016 remaining patients, 269 withdrew before the end of the study.  
Using the Fisher exact test, it was calculated that 20% of the withdrawals were due to 
treatment failure.5  It is noted that patients in the placebo group withdrew at a significantly 
faster rate than those in active treatment groups.  There were no significant differences in 
withdrawal rates across the four active treatment groups.5  
The PaGAA and PhGAA assessments are measured on a 5 point categorical scale 
where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor.  PAAP-VAS is a patient 
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questionnaire measured on a scale of 1-100mm where 0=no pain and 100=most severe pain.  
The WOMAC indices include pain, stiffness, physical function, and composite; data was 
reported for stiffness (scale 0-8) and composite (scale 0-96).  In order to establish statistical 
significance, the Hochberg procedure was used for Valdecoxib 10mg and 20mg to calculate 
p-values.  A p-value of 0.05 was used for Valdecoxib 5mg and placebo.5  
 The LSM change for PaGAA was significantly improved at most assessments for 
10mg and 20mg of Valdecoxib QD compared to placebo.5  Valdecoxib 5mg QD did not 
reach statistical significance.5  Using the PhGAA, significant improvements were observed at 
all doses and assessments.  The PAAP-VAS displayed a significant improvement in pain for 
Valdecoxib 20mg QD, while 10mg and 5mg daily doses were significantly better than 
placebo at all assessments except for week 12.5  The experimental study treatments improved 
WOMAC indices compared to placebo at 2, 6, and 12 weeks.  Valdecoxib 20mg produce a 
statistically significant change in all WOMAC scores compared to placebo.  Valdecoxib 
10mg daily only showed a statistically significant improvement in indices at week 2.5  Data is 
shown in Table 2.  
Table 2: Kivitz et al5 least square mean changes from baseline in PaGAA, PhGAA, 
PAAP-VAS, and WOMAC indices. 
 Placebo (n=205) Valdecoxib 5mg QD 
(n=201) 
Valdecoxib 10mg QD 
(n=205) 
Valdecoxib 20mg QD 
(n=201) 
PhGAA§     
Baseline Mean 4.10 4.07 4.09 4.09 
LSM change 
Week 2 (CI) -1.04 (-1.16, -
0.91) 
-1.31‡ (-1.44, - 1.19) -1.37‡ (-1.50, -1.25) -1.42‡ (-1.54, - 1.29) 
Week 6 (CI) -1.22 (-1.35, -
1.08) 
-1.44* (-1.58, - 1.31) -1.50† (-1.63, -1.36) -1.41* (-1.55, - 1.28) 
Week 12 (CI) -1.22 (-1.36, -
1.08) 
-1.43* (-1.58, -1.28) -1.52† (-1.67, -1.38) -1.45* (-1.60, -1.31) 
PAAP£     
Baseline Mean 71.20 71.41 72.41 72.54 
LSM change 
Week 2 (CI) -21.19 (-24.80, - -28.46† (-32.11, - 24.82) -30.21‡ (-33.83, -26.59) -32.07‡(-35.73, -
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17.58) 28.41) 
Week 6 (CI) -23.92 (-27.72, -
20.12) 
-30.81† (-34.65, - 26.97) -29.85* (-33.67, -26.04) -32.28† (-36.13, -
28.42) 
Week 12 (CI) -25.97 (-30.02, -
21.92) 
-31.33 (-35.42, - 27.24) -30.41 (-34.47, -30.41) -32.70* (-36.81, -
32.70) 
WOMAC OA, 
Stiffness¶ 
    
Baseline Mean 4.84 4.87 4.91 4.73 
LSM change 
Week 2 (CI) -0.78 (-0.98, -
0.57) 
-1.03 (-1.24, - 0.82) -1.20† (-1.41, -0.99) -1.24† (-1.45, -1.03) 
Week 6 (CI) -1.04 (-1.27, -
0.82) 
-1.25 (-1.48, - 1.02) -1.42* (-1.65, -1.20) -1.43* (-1.66, -1.20) 
Week 12 (CI) -1.12 (-1.36, -
0.89) 
-1.33 (-1.57, - 1.09) -1.41 (-1.65, -1.17) -1.46* (-1.70, -1.22) 
WOMAC OA, 
Composite# 
    
Baseline Mean 53.49 53.03 54.73 53.42 
LSM change 
Week 2 (CI) -10.13 (-12.28, -
7.99) 
-13.26* (-15.42, - 11.09) -15.05‡ (-17.20, -12.90) -15.44‡ (-17.63, -
13.32) 
Week 6 (CI) -12.98 (-15.45, -
10.51) 
-15.47 (-17.97, - 12.98) -16.74* (-19.22, -14.26) -17.33* (-19.48, -
14.51) 
Week 12 (CI) -13.48 (-16.07, -
10.89) 
-16.84 (-19.46, - 14.23) -17.34* (-19.93, -14.74) -17.22* (-20.64, -
15.44) 
*P < .05 vs placebo, significant. 
† P < .01 vs placebo, significant. 
‡ P < .001 vs placebo, significant. 
§ Scale = 1 (very good) to 5 (very poor). 
£ Scale = 0 mm (no pain) to 100 mm (most severe pain). 
¶ Scale = 0 (no symptoms) to 8 (worse symptoms). 
# Scale = 0 (no symptoms) to 96 (worse symptoms). 
CI, 95% confidence interval; LSM, least square mean; PAAP, Patient’s Assessment of Arthritis Pain; PhGAA, 
Physician’s Global Assessment of Arthritis; QD, once daily; WOMAC OA, Western Ontario and McMaster’s 
Universities Osteoarthritis Index. 
**This information was pulled directly from Kivitz et al5 
 Makarowski et al6 had a total of 467 patients randomized in the ITT population, 209 
of which withdrew before the end of the study period.6  Withdrawal due to treatment failure 
in the Valdecoxib 5mg & 10mg groups was significantly lower than placebo where p≤ 0.05.  
It is also noted that withdrawal from the placebo group occurred at a faster rate than any of 
the treatment groups.6 This study design was very similar to the one described in Kivitz et al, 
so the assessment tools and indices were using the same scales as stated above. 
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 In assessment of efficacy, it was shown that Valdecoxib 5mg QD & 10mg QD were 
significantly superior to placebo for all assessments.6  The only exception to this was in the 
PAAP-VAS week 12 assessment where only Valdecoxib 10mg QD was statistically superior 
to placebo.6  A summary of the data from Makarowski et al can be found in Tables 3 and 4.  
This study included all continuous data that could not be converted to dichotomous data. 
 
Table 3: Makarowski et al6 least square mean changes from baseline for PaGAA, 
PhGAA, PAAP-VAS. 
 Placebo (N=117) Valdecoxib 5mg QD 
(N=120) 
Valdecoxib 10mg QD 
(N=111) 
PaGAA ‡    
Baseline mean 4.1 4.1 4.1 
LSM change 
Week 2 -0.72 -1.10**† -1.26***† 
Week 6 -0.82 -1.11*† -1.29***† 
Week 12 -0.87 -1.20*† -1.29***† 
PhGAA‡    
Baseline mean 4.1 4.1 4.1 
LSM change 
Week 2 -0.72 -1.10**† -1.22***† 
Week 6 -0.84 -1.17*† -1.25**† 
Week 12 -0.88 -1.18* -1.25* 
PAAP-VAS§    
Baseline mean 71.2 72.3 73.4 
LSM change 
Week 2 -14.4 -21.0* -24.6** 
Week 6  -16.0 -23.3* -25.8** 
Week 12 -15.2 -21.3 -23.2* 
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.  
†Statistically significantly different from placebo in pairwise comparisons.  
‡Scale ranged from 1 (very good) to 5 (very poor).  
§Scale ranged from 0–100 mm, with 0=no pain and 100=most severe pain. 
*Information was pulled directly from Makarowski et al6 
 
Table 4: Makarowski et al6 least square mean changes from baseline for WOMAC indices. 
 Placebo (N=117) Valdecoxib 5mg 
QD (N=120) 
Valdecoxib 10mg QD 
(N=111) 
Pain index§    
Baseline mean 10.8 11.2 10.8 
LSM change 
Week 2 -0.90 -2.48***‡ -2.56***‡ 
Week 6 -1.09 -2.76***‡ -3.23***‡ 
Week 12 -1.25 -2.54*‡ -2.83**‡ 
Composite index¶    
Baseline mean 52.6 54.7 52.8 
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LSM change 
Week 2 -4.31 -10.8** -12.6*** 
Week 6 -5.07 -12.3** -14.7*** 
Week 12 -5.28 -12.0** -14.0*** 
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.  
‡Statistically significantly different from placebo in pairwise comparisons according to 
Hochberg’s procedure.  
§Scale ranged from 0 to 20, with lower score as better.  
¶Scale ranged from 0 to 96, with lower score as better. 
*Information was pulled directly from Makarowski et al6  
 
 The study design for Moskowitz et al7 was still looking at efficacy of Valdecoxib, but 
not as a long term treatment.  They were assessing the quickness of onset of analgesia during 
acute pain flare.  In order to be included in the ITT population, patients were screened 
according to inclusion and exclusion data described in Table 1 and then randomized and 
given at least one study medication.7  The ITT population included 435 patients, but 95 
patients were then excluded from the per protocol (PP) cohort due to various reasons 
described in the study.7  
 Pain intensity difference (PID) VAS scores were significantly greater in the 
Valdecoxib treatment group at 4 hours versus placebo.7  Median time to first onset of 
analgesia in the PP cohort was also significantly shorter for Valdecoxib as compared to 
placebo.  Also, Valdecoxib had significantly improved Summed PID (SPID) scores in the 
first 6 hours compared to placebo.7  Analgesic onset in the ITT population showed a 
significant percentage of patients with onset of analgesia from 4hrs to 6hrs, shown in Table 
5.7 This study included some dichotomous data that could be calculated to show that the 
NNT for Valdecoxib 10mg was 7; meaning that 7 patients need to be treated with this 
medication in order to have a positive impact on one. This data is shown in Table 6.   
Table 5: Percent incidence of onset of analgesia during the first 6hrs in ITT population7 
Time (h) Valdecoxib 10mg QD (n=212) Placebo (n=110) 
1.0 29 28 
2.0 46 39 
3.0 50 41 
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4.0 55* 40 
5.0 56* 42 
6.0 58* 43 
*P < 0.05 
*Information pulled directly from Moskowitz et al7 
 
Table 6: Calculated data for treatment using dichotomous data 
  Relative benefit 
increase (RBI) 
Absolute Benefit 
increase (ABI) 
Number Needed to 
treat (NNT) 
CER EER EER-CER 
   CER 
EER-CER 1/ABI 
40% 
 
55% 0.375 0.15 7 
Where p-value ≤ 0.05 vs placebo 
 
DISCUSSION 
 The populations studied in each article were relatively similar, with mean age ranging 
from 59.7 years to 63.9 years old.  All studies had similar inclusion and exclusion criteria, 
assuring that all patients were considered to have significant disease before the studies were 
done.  There were similar results as far as efficacy of Valdecoxib, showing it to be significant 
to placebo at doses equal to and greater than 10mg QD.  Kivitz et al did not find Valdecoxib 
5mg QD to be significant to placebo, requiring further evaluation of a proper daily dosage.5   
One aspect of this drug that has been evaluated in other studies is its safety.  The 
original thought behind COX-2 inhibitors was to improve GI safety compared to NSAIDS, 
but drugs like Valdecoxib have displayed safety issues in other areas like cardiovascular 
events.8  As part of the sulfonamide class, Valdecoxib already carries increased risk for 
reactions including TEN, SJS, and erythema multiforme.8    
CONCLUSION 
 Based on the information provided in these three studies, it has been concluded that 
Valdecoxib is an effective treatment for pain in patients with Osteoarthritis of the hip or knee 
compared to placebo at doses of 10mg and higher; however, there are several issues with 
these studies that would require further examination.  One main concern is the withdrawal 
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rates for all three articles were very high, reducing the validity of each of them significantly.  
Although it was shown by Kivitz et al5 and Makarowski et al6 that withdrawal number and 
rates were higher in placebo than treatment groups, there was still a significant amount of 
participants withdrawing from experimental groups due to treatment failure.   
The second issue with Valdecoxib in general is that in recent studies, safety has been 
evaluated leading the FDA to take Valdecoxib off the market completely in 2005.8  Further 
studies have clearly showed that the risks outweighed the benefits of Valdecoxib in the 
treatment of Osteoarthritis; however there are still many COX-2 inhibitors on the market to 
treat Osteoarthritis that did not have the cardiovascular events that Valdecoxib did.  By 
researching Valdecoxib or other failed treatment options we can provide insight to future 
prospects in pain management for Osteoarthritis.  
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